Navigation Links
Cardiosolutions, Inc. Gathers Major Investment from Sorin Group
Date:7/10/2012

WEST BRIDGEWATER, Mass., July 10, 2012 /PRNewswire/ -- Cardiosolutions, Inc. an early-stage company focused on the development of an innovative percutaneous system to treat patients with moderate to severe mitral valve regurgitation, today announced it has received a minority investment from Sorin Group (Reuters Code: SORN.MI), a global medical device company and an international leader in the treatment of cardiovascular disease.

Cardiosolutions' technology consists of a proprietary catheter delivery system and an implant, the Mitra-Spacer™. This implant is designed to fill the void created by a dilated annulus or deteriorating valve mechanism providing a sealing surface for the leaflets of the mitral valve, thus reducing the degree of mitral regurgitation in patients.

This cutting-edge technology represents a less invasive, percutaneous solution for patients who suffer from moderate to severe mitral regurgitation, including a portion of those who have congestive heart failure. Today two to three percent of the world's population suffers from mitral regurgitation and approximately 2.3 million patients in the US and Europe suffer from severe mitral regurgitation. Every year approximately 500,000 new patients are diagnosed with this disease, of which over 80% are untreated.  A substantial group of patients have no option because they are too sick to survive the surgery and many others delay treatment because they have only moderate symptoms. All these patients could benefit from a less invasive solution.

Sorin's $8 million investment will finance on-going product development and clinical testing of this technology. Under the terms of the agreement, Sorin also has an option to acquire the company in the future. Sorin Group joins STD Med and BioVentures Investors as an investor in Cardiosolutions.

"We are very pleased to have Sorin Group, a leading Global medical device company, as our strategic partner in Cardiosolutions.
'/>"/>

SOURCE Cardiosolutions, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cardiosolutions, Inc. Receives FDA 510(k) Clearance for Dexterity™ Steerable Introducer
2. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
3. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
4. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
5. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
6. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
7. Intrepid Investment Bankers LLC Advises Newport Medical Instruments, Inc. in its Sale to Covidien plc
8. Johnson & Johnson (China) Investment Ltd. Acquires Guangzhou Bioseal Biotechnology Co., Ltd.
9. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
10. Novogen Board Approves US$4 Million Investment In Marshall Edwards Rights Offering
11. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 ... International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare, ... senior service industry, will be held at Shanghai New ... On 25 February, 2015,  Implementation Suggestions on Encouraging Private ... Industry, which was jointly issued by the Ministry of ...
(Date:3/27/2015)... 2015 According to a new ... (Conventional, Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab ... VT, WPW) - Global Forecasts to 2019 ", published by ... around ~$4.73 Billion by 2019 with a CAGR of ... Browse   90   ma ...
(Date:3/27/2015)... DALLAS , March 27, 2015   ... global leader in biosimilars and the world,s leading ... two studies that support an evaluation of biosimilarity ... U.S. Food and Drug Administration (FDA) conditionally approved ... Amgen,s EPOGEN™ (epoetin alfa). These study data were ...
Breaking Medicine Technology:CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 2CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 3CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 4CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 5CHINA AID, the 10th China International Exhibition of Senior Care, Rehabilitation Medicine and Healthcare to be held in April 6Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3
... DIEGO, Oct. 19 Ceregene, Inc., a biopharmaceutical company, ... double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in ... that delivers the neurotrophic factor neurturin to degenerating or ... clinical trial of CERE-120 are being published later this ...
... PRGO ; TASE) today announced that it will release ... November 2, 2010 at approximately 8:00 a.m. (ET).  The Company ... by Joseph C. Papa, Perrigo,s Chairman and Chief Executive Officer. ... webcast to interested parties on the Perrigo website http://www.perrigo.com ...
Cached Medicine Technology:Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 2Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 3Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 4Ceregene Initiates a New Controlled Phase 2b Trial of CERE-120 for Parkinson's Disease 5
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... Foundation for Women’s Cancer announce today that ... 2015 recipient of the Claudia Cohen Research Foundation Prize ... presented at the Society of Gynecologic Oncology 46th Annual ... is Director of the Cedars-Sinai Women’s Cancer Program at ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
(Date:3/28/2015)... The California-based leading wig brand UniWigs ... shopping on UniWigs during the Easter Holidays from today ... promotion on April Fools’ Day. , As the winter ... the corner. Easter Festival, with religious origins to countries ... holiday after Christmas. The best wig provider, UniWigs, would ...
(Date:3/28/2015)... Vegas, NV (PRWEB) March 28, 2015 Pitching ... with a history of shoulder and elbow injuries, according to ... Sports Medicine’s ( AOSSM ) Specialty Day. , “Our findings ... with a 20% increase in likelihood of a history of ... associated with a 12% increase likelihood of a history of ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3Health News:UniWigs Is Sending Out Mysterious Gifts During the Easter Holidays 2Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2
... ... parenting tips for teens , ... Washington, DC (Vocus) October 16, 2009 -- More than 30 pediatric experts from Children’s ... Conference and Exhibition, which runs from October 16 – 19 in Washington. , , , ...
... SAN ANTONIO, Oct. 16 The National Trauma Institute, ... in the United States, announced its first Request for ... to change medical practice and save lives. , The ... translational research to take place in 2010. "Historically, trauma ...
... Friday, October 16, U.S. President Barack Obama will join U.S. ... Texas to celebrate the 20th Anniversary of Points of Light ... in their communities. , The anniversary marks President Bush,s inauguration ... of Light" to salute and encourage individuals to solve problems ...
... Pa., Oct. 16 Amgen (Nasdaq: AMGN ) ... scientific data about ENBREL being presented at the 2009 ... Pa., from Oct. 17-21, 2009. These presentations contribute to ... , "The clinical data being presented at ...
... Rotary International has declared October 24, 2009, "World Polio Day" ... In the past 10 years alone Rotarians in Alaska and ... of a polio-free world. They have also traveled to places ... national immunization days. , In 1985, Rotary International joined with ...
... will allow public forum for discussing the latest updates, information on ... of the public are invited to submit questions for inclusion in ... Thursday, Oct. 22, from 10 a.m. - noon on Twitter. ... of Michigan Health System and VA Ann Arbor Healthcare System, will ...
Cached Medicine News:Health News:Children's National Experts Presenting at American Academy of Pediatrics Conference, 2Health News:National Trauma Institute Announces $600,000 in Funding for Trauma Research 2Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 2Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 3Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 4Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 5Health News:President Barack Obama Joins President George H.W. Bush to Celebrate the 20th Anniversary of the 'Points of Light' Volunteer Movement and Extend the Call of Service to the Nation 6Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 2Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 3Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 4Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 5Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 6Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 7Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 8Health News:Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientific Meeting 9
... gentle and effective surgical scrub with special ... is known to kill skin surface pathogens, ... protozoa and yeasts. It produces a rich ... pre-operative prepping, as well as for pre-and ...
... Aplicare two and four ounce ... meet the needs of procedural ... bottle itself has been custom ... match the cap perfectly. This ...
A patient skin prepping solution in a self-contained applicator combining two proven broad-spectrum antimicrobials: alcohol for fast kill and fast drying (3 minutes on skin), and an iodophor for pers...
Idophor PVP Scrub Winged Sponges...
Medicine Products: